Dahl MV: “Host Defense: Herpes, Warts and Other Viruses,” in Clinical Immunodermatology, 2nd Ed, Year Book Medical Publishers, Chicago. ,1988. .
Griswold DE, Alessi S, Badger A, et al: Inhibition of T suppressor cell expression by histamine type 2 (H2) receptor antagonists. .J Immunol 132::3054. ,1984. .
Orlow S, Paller A: Cimetidine therapy for multiple viral warts in children. .J Am Acad Dermatol 28::794. ,1993. .
Siegfried EC: Warts and molluscum: an approach to therapy. .Dermatol Ther 12::51. ,1997. .
Glass S: Cimetidine therapy for recalcitrant warts in adults. .Arch Dermatol 132::680. ,1996. .
Mahoney JM: Oral cimetidine and the treatment of verrucae. .JAPMA 86::183. ,1996. .
Yilmaz E, Alpsoy E, Basaran E: Cimetidine therapy for warts: a placebo-controlled, double-blind study. .J Am Acad Dermatol 34::1005. ,1996. .
Karabulut AA, Sahin S, Eksioglu M: Is cimetidine effective for non-genital warts? a double-blind, placebo-controlled study. .Arch Dermatol 133::533. ,1997. .
Can cimetidine therapy effectively stimulate the body’s immune response against warts? Several clinicians have anecdotally reported success using cimetidine against warts. Previous double-blind studies comparing cimetidine with placebo therapy have failed to statistically and scientifically corroborate those results. Between 1995 and 2002, 216 patients underwent an isolated course of oral cimetidine therapy for verruca plantaris. Our treatment outcomes closely parallel those obtained by other researchers. Cimetidine may be used as a safe, effective, lone treatment modality for verruca in all age groups. (J Am Podiatr Med Assoc 95(3): 229–234, 2005)